Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
2,108
archived clinical trials in
Lupus

A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Inlande Rheumatology Clinical Trials
mi
from
Upland, CA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Inlande Rheumatology Clinical Trials
mi
from
Upland, CA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Denver Arthritis Center
mi
from
Denver, CO
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Denver Arthritis Center
mi
from
Denver, CO
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
New Horizon Research Center
mi
from
Miami, FL
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
New Horizon Research Center
mi
from
Miami, FL
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
West Broward Rheumatology Associates, Inc.
mi
from
Tamarac, FL
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
West Broward Rheumatology Associates, Inc.
mi
from
Tamarac, FL
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research of West Florida, Inc.
mi
from
Tampa, FL
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research of West Florida, Inc.
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Kansas City Internal Medicine Research
mi
from
Overland Park, KA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Kansas City Internal Medicine Research
mi
from
Overland Park, KA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Arthritis and Diabetes Clinic, Inc
mi
from
Monroe, LA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Arthritis and Diabetes Clinic, Inc
mi
from
Monroe, LA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Louisiana State University Health Sciences Center
mi
from
Shreveport, LA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Louisiana State University Health Sciences Center
mi
from
Shreveport, LA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
University of Michigan
mi
from
Ann Arbor, MI
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Arthritis Consultants
mi
from
Saint Louis, MO
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Arthritis Consultants
mi
from
Saint Louis, MO
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Albuquerque Clinical Trials
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
North Shore University Hospital at Great Neck
mi
from
Great Neck, NY
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
North Shore University Hospital at Great Neck
mi
from
Great Neck, NY
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Ohio State University
mi
from
Columbus, OH
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Ohio State University
mi
from
Columbus, OH
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Paramount Medical Research
mi
from
Middleburg Heights, OH
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Paramount Medical Research
mi
from
Middleburg Heights, OH
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Arthritis & Rheumatology Center Of Oklahoma Pllc
mi
from
Oklahoma City, OK
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Arthritis & Rheumatology Center Of Oklahoma Pllc
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Oklahoma Medical Research Foundation
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
The Oklahoma Center For Arthritis Therapy
mi
from
Tulsa, OK
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
The Oklahoma Center For Arthritis Therapy
mi
from
Tulsa, OK
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
East Penn Rheumatology
mi
from
Bethlehem, PA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
East Penn Rheumatology
mi
from
Bethlehem, PA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clinical Research Center of Reading, LLC
mi
from
Wyomissing, PA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clinical Research Center of Reading, LLC
mi
from
Wyomissing, PA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Accent Clinical Research Professionals, LLC
mi
from
Allen, TX
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Accent Clinical Research Professionals, LLC
mi
from
Allen, TX
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Investigational Site Number 032302
mi
from
Ciudad Autonoma De Buenos Aire,
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Investigational Site Number 032302
mi
from
Ciudad Autonoma De Buenos Aire,
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
University of California
mi
from
La Jolla, CA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
University of California
mi
from
La Jolla, CA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Wallace Rheumatic Study Center
mi
from
Beverly Hills, CA
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Wallace Rheumatic Study Center
mi
from
Beverly Hills, CA
Click here to add this to my saved trials
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated:  12/31/1969
Clayton Medical Research
mi
from
Saint Louis, MO
A Study of Baricitinib (LY3009104) in Participants With Systemic Lupus Erythematosus (SLE)
A Randomized, Double-Blind, Placebo-Controlled, Parallel- Group, Phase 2 Study of Baricitinib in Patients With Systemic Lupus Erythematosus (SLE)
Status: Enrolling
Updated: 12/31/1969
Clayton Medical Research
mi
from
Saint Louis, MO
Click here to add this to my saved trials
Walk With Ease Program For Patients With Systemic Lupus Erythematosus
Walk With Ease Program For Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
UNC Rheumatology Clinic
mi
from
Chapel Hill, NC
Walk With Ease Program For Patients With Systemic Lupus Erythematosus
Walk With Ease Program For Patients With Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
UNC Rheumatology Clinic
mi
from
Chapel Hill, NC
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 302
mi
from
Upland, CA
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 302
mi
from
Upland, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 304
mi
from
Clearwater, FL
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 304
mi
from
Clearwater, FL
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 301
mi
from
Miami Lakes, FL
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 301
mi
from
Miami Lakes, FL
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 321
mi
from
Miami, FL
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 321
mi
from
Miami, FL
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 310
mi
from
Tampa, FL
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 310
mi
from
Tampa, FL
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 317
mi
from
Amarillo, TX
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 317
mi
from
Amarillo, TX
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 312
mi
from
Birmingham, AL
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 312
mi
from
Birmingham, AL
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 307
mi
from
El Cajon, CA
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 307
mi
from
El Cajon, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 309
mi
from
El Cajon, CA
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 309
mi
from
El Cajon, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 323
mi
from
Huntington Beach, CA
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 323
mi
from
Huntington Beach, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 311
mi
from
Los Angeles, CA
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 311
mi
from
Los Angeles, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 314
mi
from
Thousand Oaks, CA
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 314
mi
from
Thousand Oaks, CA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 322
mi
from
Debary, FL
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 322
mi
from
Debary, FL
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 319
mi
from
Palm Harbor, FL
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 319
mi
from
Palm Harbor, FL
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 324
mi
from
Atlanta, GA
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 324
mi
from
Atlanta, GA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 327
mi
from
Stockbridge, GA
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 327
mi
from
Stockbridge, GA
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 320
mi
from
Idaho Falls, ID
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 320
mi
from
Idaho Falls, ID
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 306
mi
from
Albuquerque, NM
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 306
mi
from
Albuquerque, NM
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 313
mi
from
Lake Success, NY
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 313
mi
from
Lake Success, NY
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 315
mi
from
Jackson, TN
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 315
mi
from
Jackson, TN
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 308
mi
from
Memphis, TN
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 308
mi
from
Memphis, TN
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 305
mi
from
Oklahoma City, OK
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 305
mi
from
Oklahoma City, OK
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 303
mi
from
Houston, TX
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 303
mi
from
Houston, TX
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 326
mi
from
New Haven, CT
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 326
mi
from
New Haven, CT
Click here to add this to my saved trials
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated:  12/31/1969
Sl0023 101
mi
from
Plovdiv,
A Phase 2 Efficacy and Safety Study of Dapirolizumab Pegol (DZP) in Systemic Lupus Erythematosus
A Multi-center, Randomized, Double-blind, Placebo-controlled, Parallel-group, Dose-ranging Study Followed by an Observational Period to Evaluate the Efficacy and Safety of Dapirolizumab Pegol in Subjects With Moderately to Severely Active Systemic Lupus Erythematosus
Status: Enrolling
Updated: 12/31/1969
Sl0023 101
mi
from
Plovdiv,
Click here to add this to my saved trials